Impact of CAR T-cell therapy in Earlier Lines of MM

Opinion
Video

A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.

Video content above is prompted by the following:

  • Let’s talk about the use of CAR T-cell therapy in early R/R MM. Please share your thoughts on the following data:
  • CARTITUDE-4
  • KarMMa-3
  • How does the CAR T-cell fit into 2nd line treatment in your practice and in which patients do you use CAR T-cell in?
  • How does CAR T-cell therapy in the 2nd line affect your approach to front-line therapy for MM?
Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content